Cologuard
Commercial- Indications
- Colorectal cancer screening
Company intelligence / Profile preview
Exact Sciences
Madison, Wisconsin, United Statesexactsciences.com ↗
- Ownership
- Public · EXAS
- Employees
- ~6849
- Development stage
- Commercial
01
Overview
Exact Sciences offers FDA-approved tests for cancer screening and diagnostics, including Cologuard for colorectal cancer screening and Oncotype DX for breast cancer treatment guidance. They also have a pipeline focused on multi-cancer early detection.
- Therapeutic areas
- OtherOncology
- Modalities
- Genomic testingDNA methylationMolecular diagnostics
- Industry
- Molecular Diagnostics
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $20B
- Total revenue
- $878.4M
- Enterprise value
- $21.6B
Beyond the preview
Go deeper on Exact Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exact Sciences.